Loading…
Single‐Entity Hydrocodone Extended‐Release Capsules in Opioid‐Tolerant Subjects with Moderate‐to‐Severe Chronic Low Back Pain: A Randomized Double‐Blind, Placebo‐Controlled Study
Objective A single‐agent, extended‐release formulation of hydrocodone (HC) has been developed for treatment of chronic moderate‐to‐severe pain. This study was designed to examine the safety and efficacy of HC extended release in opioid‐experienced adults with moderate‐to‐severe chronic low back pain...
Saved in:
Published in: | Pain medicine (Malden, Mass.) Mass.), 2014-06, Vol.15 (6), p.975-985 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Objective
A single‐agent, extended‐release formulation of hydrocodone (HC) has been developed for treatment of chronic moderate‐to‐severe pain. This study was designed to examine the safety and efficacy of HC extended release in opioid‐experienced adults with moderate‐to‐severe chronic low back pain (CLBP).
Methods
This multicenter, enriched enrollment, randomized withdrawal study comprised an open‐label conversion/titration phase (≤6 weeks) followed by placebo‐controlled, double‐blind treatment (12 weeks). During the conversion/titration phase, subjects (N = 510) converted from their current opioid and were titrated to a stabilized dose of HC extended release (20−100 mg every 12 hours). During treatment, subjects (N = 151 per group) received HC extended release or placebo; rescue medication was permitted. The primary efficacy end point was mean change in average pain intensity from baseline to day 85. Response rates (30% pain improvement) and satisfaction (Subject Global Assessment of Medication) were assessed.
Results
Demographic and baseline characteristics were similar between groups. Mean ± SD change in average pain intensity score from baseline to day 85 was significantly lower in the HC extended‐release treatment group vs placebo (0.48 ± 1.56 vs 0.96 ± 1.55; P = 0.008). Significantly more responders were in the treatment group (68% vs 31%; P |
---|---|
ISSN: | 1526-2375 1526-4637 |
DOI: | 10.1111/pme.12377 |